You are leaving Opioid Dependence.com. Links are provided as a public service and for informational purposes only.

Cancel Continue

You are leaving Opioid Dependence.com. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Clicking on "Continue" will take you to a website that is outside the control of Reckitt Benckiser. You are solely responsible for your interactions with such websites.

Cancel Continue

Biological Basis of Dependence
Comorbid Psychiatric Conditions
The incidence of psychiatric comorbidities among those with substance abuse disorders is higher than that seen in the general population. Opioid dependence is no exception:
  • 39% to 47% of patients who seek treatment for opioid dependence have documented psychiatric comorbidities1
  • Opioid users have a significantly higher rate of depression (16%) compared with non-opioid users (6%)2,3

Besides depression, the psychiatric disorders most commonly seen in opioid-dependent patients are1:

  • Other substance abuse disorders
  • Post-traumatic stress disorders
  • Antisocial and borderline personality disorders

Although the etiological role of psychiatric disorders in the genesis of opioid dependence is still unclear, there is reasonable evidence that many patients initially turn to substance use in an effort to self-medicate an untreated psychiatric condition.4 For these reasons, physicians should be alert to the possibility of untreated psychiatric conditions.5

At the same time, not all patients who exhibit symptoms actually have an underlying psychiatric disorder—substance abuse can mimic, exacerbate, or precipitate psychiatric symptoms and disorders.1 Assessment is fundamental to determining whether symptoms reflect a primary psychiatric disorder or substance-induced condition.1

Diagnosis of psychiatric disorders (or referral to someone who can) is critical to matching patients to the most suitable care.1 The presence of comorbid psychiatric disorders does not preclude a patient's being treated with office-based or other pharmacotherapy, it simply means the condition should be addressed simultaneously by an appropriate healthcare professional.1

Back to Top
References
1. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
2. Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:71-80.
3. National Institute of Mental Health. Depression. Available at: www.nimh.nih.gov/publicat/depression.cfm. Accessed April 26, 2005.
4. Merck & Co., Inc. Pediatrics—psychiatric conditions in childhood and adolescence. In: Beers MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy. 17th ed (online). 1999-2005.
5. Buprenorphine in the Treatment of Opioid Dependence [training CD-ROM]. Prairie Village, Kan: American Academy of Addiction Psychiatry; 2002.
Get Information about Office-based Treatment

This site is intended for use by US residents only.
© Copyright 2005. All Rights Reserved.